INOVIO Pharmaceuticals
NEWS ALERT

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

Archive: April 2026

INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Posted on April 16, 2026

INOVIO to Participate in Upcoming Scientific Conference

Posted on April 16, 2026

INOVIO Announces Pricing of $17.5 Million Public Offering

Posted on April 16, 2026

INOVIO Announces Proposed Public Offering

Posted on April 16, 2026

INOVIO to Participate in Upcoming Scientific Conferences

Posted on April 16, 2026

FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Posted on April 16, 2026

INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

Posted on April 16, 2026

INOVIO Reports Inducement Grant Under Inducement Plan

Posted on April 16, 2026

INOVIO to Participate in Upcoming Scientific and Investor Conferences

Posted on April 16, 2026

INOVIO Announces Pricing of $17.5 Million Public Offering

Posted on April 2, 2026

© Copyright 2026 INOVIO Pharmaceuticals. All rights reserved.